Oncosoft (CEO Kim Jinsung), a medical AI company specializing in radiation therapy, announced on the 24th that its veterinary radiation therapy software, 'OncoVET,' has received a Class 2 animal medical device license from the Animal and Plant Quarantine Agency.
An Oncosoft official stated, "OncoVET is the first radiation therapy planning software to be licensed as a veterinary medical device." The official added, "Furthermore, OncoVET 1.0.0 has been installed for research purposes at the Seoul Animal Imaging and Oncology Center (Helix Animal Medical Center), and we are conducting joint research to verify its applicability in a real clinical environment."
OncoVET was developed based on Oncosoft's radiation therapy solution, 'OncoStudio.' It optimizes OncoStudio's precision image registration and automatic structure segmentation technology for veterinary anatomical structures. This allows for the creation of precise radiation therapy plans for companion animals at a level comparable to human treatment. Oncosoft stated that the commercialization of this solution is expected to increase the efficiency of radiation therapy, significantly reducing the waiting time for treatment for companion animals.
OncoVET provides an auto-contouring system that uses AI to automatically segment more than 28 anatomical structures in the head and neck region. It takes into account breed-specific anatomical characteristics and changes in posture. Furthermore, its automated self-configuring architecture maintains consistent performance in clinical settings.
Earlier this year, Oncosoft signed a Non-Disclosure Agreement (NDA) with the University of Florida College of Veterinary Medicine and is developing an AI model tailored for the North American market.
Ju-Young Son, head of Oncosoft's U.S. branch, said, "The commercialization of OncoVET will reduce the time and reliance on specialized personnel for radiation therapy planning." He added, "We expect innovation in the global veterinary radiation therapy market, with a focus on North America."
Oncosoft CEO Kim Jinsung stated, "The veterinary medical device license and the research installation at the Seoul Animal Imaging and Oncology Center demonstrate the excellence of OncoVET's technology." He concluded, "We will set a new standard of AI-based precision medicine in companion animal cancer treatment and expand our entry into the global veterinary medical market."
